<DOC>
	<DOCNO>NCT02239172</DOCNO>
	<brief_summary>The purpose study evaluate compare safety , reactogenicity , tolerability PA83-FhCMB vaccine candidate deliver 4 dose level Alhydrogel</brief_summary>
	<brief_title>PA83-FhCMB Plant-Derived Recombinant Protective Antigen ( rPA ) Anthrax Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Citizen permanent resident US Male female age 18 49 year inclusive Able give write informed consent Healthy , determine medical history , physical examination , vital sign , clinical safety laboratory examination baseline Females fulfill one follow criterion : 1 . At least one year postmenopausal 2 . Surgically sterile 3 . Willing use medically approve form contraception ( eg , oral , implantable , transdermal , injectable hormonal contraceptive ; intrauterine device ; barrier protection include female condom , diaphragm , cervical cap , male condom conjunction spermicide ) 30 day prior first vaccination end study 4 . Willing abstain sexual intercourse 30 day prior first vaccination end study Women childbearing potential must negative urine pregnancy test within 24 hour precede receipt dose Comprehension study requirement Expressed availability require study period Ability attend schedule visit contact telephone throughout followup period History anthrax disease receipt anthrax vaccine Presence significant uncontrolled medical psychiatric illness ( acute chronic ) include institution new medical surgical treatment significant dose alteration uncontrolled symptom drug toxicity within 3 month screen Positive serology HIV1 HIV2 , HBsAg HCV antibodies Pregnancy lactation Cancer treatment cancer , within previous 3 year , exclude basal cell carcinoma Presence medical condition may associate impaired immune responsiveness , include diabetes mellitus , per investigator 's discretion Presently receive history receiving , precede 3month period , medication treatment may adversely affect immune system 1 . This include allergy injection , immune globulin , interferon , immunomodulators , cytotoxic drug , systemic corticosteroid ( oral injectable ; 20 mg/day x 14 day longer ) 2 . Radiation therapy 3 . Intranasal topical corticosteroid allow Receipt plan administration non study vaccine within 14 day prior vaccination throughout study period ( 30 day live vaccine ) Immunization emergency basis Tetanus Toxoids Adsorbed adult use ( Td Tdap ) influenza vaccine 14 day least 14 day dose study vaccine allow History anaphylactic type reaction inject vaccine History drug chemical abuse year study Receipt investigational product nonregistered drug within 30 day prior vaccination currently enrol investigational drug study intend enroll study within ensue study period Receipt blood blood product 8 week prior vaccination plan administration study period Donation blood blood product within 8 week prior vaccination time study Acute disease within 72 hour prior vaccination 1 . Acute disease define presence moderate severe illness ( determined Investigator medical history physical examination ) without fever ( ≥38°C ; 100.4°F ) , oral temperature ≥38°C orally 2 . Study vaccine administer person minor illness History immunodeficiency , chronic illness require continuous frequent medical intervention , autoimmune disease , use immunosuppressive medication , ongoing therapy systemic corticosteroid within 3 month prior plan vaccine dose . Inhaled topical steroid permit . `` Burst '' therapy steroid permit except within 2 week prior vaccination . Evidence psychiatric , medical and/or substance abuse problem past 6 month investigator believe would adversely affect subject 's ability participate trial Occupational responsibility would prevent completion participation trial , include : 1 . US military reservist may receive licensed anthrax vaccine ( BioThrax ) serve Persian Gulf War January May , 1991 . Such individual may enrol provide medical record , show proof receive licensed anthrax vaccine . 2 . Postal worker may expose anthrax may take BioThrax Any condition , opinion investigator , might interfere interpretation data support primary study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>